Mogroside IVeCAS# 88915-64-4 |
- Mogroside IV
Catalog No.:BCN2532
CAS No.:89590-95-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 88915-64-4 | SDF | Download SDF |
| PubChem ID | 102004786 | Appearance | Powder |
| Formula | C54H92O24 | M.Wt | 1125.3 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2R,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R,6R)-6-[[(3S,8R,9R,10R,11R,13R,14S,17R)-17-[(2R,5R)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-hydroxy-6-methylheptan-2-yl]-11-hydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol | ||
| SMILES | CC(CCC(C(C)(C)O)OC1C(C(C(C(O1)CO)O)O)OC2C(C(C(C(O2)CO)O)O)O)C3CCC4(C3(CC(C5(C4CC=C6C5CCC(C6(C)C)OC7C(C(C(C(O7)COC8C(C(C(C(O8)CO)O)O)O)O)O)O)C)O)C)C | ||
| Standard InChIKey | WRPAFPPCKSYACJ-KGFBLRRZSA-N | ||
| Standard InChI | InChI=1S/C54H92O24/c1-22(9-13-33(51(4,5)70)77-49-45(41(66)36(61)28(20-57)74-49)78-48-44(69)39(64)35(60)27(19-56)73-48)23-15-16-52(6)30-12-10-24-25(54(30,8)31(58)17-53(23,52)7)11-14-32(50(24,2)3)76-47-43(68)40(65)37(62)29(75-47)21-71-46-42(67)38(63)34(59)26(18-55)72-46/h10,22-23,25-49,55-70H,9,11-21H2,1-8H3/t22-,23-,25-,26-,27-,28-,29-,30-,31-,32+,33-,34-,35-,36-,37-,38+,39+,40+,41+,42-,43-,44-,45-,46-,47+,48+,49+,52+,53-,54+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Mogroside IVe can inhibit the proliferation of HT29 and Hep-2 cells in culture and in xenografted mice in a dose-dependent manner, which is accompanied by the upregulation of tumor suppressor p53, and downregulation of matrix metallopeptidase 9 (MMP-9) and phosphorylated extracellular signal-regulated kinases (ERK)1/2. |
| Targets | p53 | ERK | MMP(e.g.TIMP) |
Mogroside IVe Dilution Calculator
Mogroside IVe Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 0.8887 mL | 4.4433 mL | 8.8865 mL | 17.773 mL | 22.2163 mL |
| 5 mM | 0.1777 mL | 0.8887 mL | 1.7773 mL | 3.5546 mL | 4.4433 mL |
| 10 mM | 0.0889 mL | 0.4443 mL | 0.8887 mL | 1.7773 mL | 2.2216 mL |
| 50 mM | 0.0178 mL | 0.0889 mL | 0.1777 mL | 0.3555 mL | 0.4443 mL |
| 100 mM | 0.0089 mL | 0.0444 mL | 0.0889 mL | 0.1777 mL | 0.2222 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- (-)-Xestospongin C
Catalog No.:BCC7002
CAS No.:88903-69-9
- Mogroside II-A2
Catalog No.:BCN3180
CAS No.:88901-45-5
- Mogroside II-A1
Catalog No.:BCN7926
CAS No.:88901-44-4
- Mogroside III-A2
Catalog No.:BCN7925
CAS No.:88901-43-3
- Mogroside III-A1
Catalog No.:BCN3170
CAS No.:88901-42-2
- Mogroside IVa
Catalog No.:BCN3165
CAS No.:88901-41-1
- Mogroside IIe
Catalog No.:BCN3168
CAS No.:88901-38-6
- Mogroside IIIe
Catalog No.:BCN7924
CAS No.:88901-37-5
- Mogroside V
Catalog No.:BCN1036
CAS No.:88901-36-4
- Bafilomycin A1
Catalog No.:BCC3914
CAS No.:88899-55-2
- Atrial natriuretic factor (1-28) (rat)
Catalog No.:BCC5843
CAS No.:88898-17-3
- Inulanolide A
Catalog No.:BCN3705
CAS No.:888941-86-4
- Mogrol
Catalog No.:BCN8446
CAS No.:88930-15-8
- Dipsanoside A
Catalog No.:BCN2877
CAS No.:889678-62-0
- Dipsanoside B
Catalog No.:BCN2878
CAS No.:889678-64-2
- Quinolinic acid
Catalog No.:BCC6573
CAS No.:89-00-9
- Edaravone
Catalog No.:BCC2480
CAS No.:89-25-8
- Mesalamine
Catalog No.:BCC4798
CAS No.:89-57-6
- Neoisomenthol
Catalog No.:BCC8169
CAS No.:20752-34-5
- (+)-Menthone
Catalog No.:BCC9239
CAS No.:89-80-5
- Pulegone
Catalog No.:BCN3856
CAS No.:89-82-7
- Thymol
Catalog No.:BCN3794
CAS No.:89-83-8
- 2,4-Dihydroxyacetophenone
Catalog No.:BCN4441
CAS No.:89-84-9
- 2'-Deoxyinosine
Catalog No.:BCN8544
CAS No.:890-38-0
Mogroside IVE attenuates experimental liver fibrosis in mice and inhibits HSC activation through downregulating TLR4-mediated pathways.[Pubmed:29268190]
Int Immunopharmacol. 2018 Feb;55:183-192.
Liver fibrosis has been emphasized as a serious threat to human health. There is currently no effective clinical drug treatment. Although mogrosides (MGs) have extensive pharmacological effects with minimal toxicity, their effects on liver function, inflammation, matrix metalloproteinases and hepatic stellate cell (HSC) activation remain to be researched. In the current study, we investigated whether Mogroside IVe (MGIVE), a main compound isolated from MGs, provided protection against liver fibrosis in mice. MGIVE (25mg/kg) significantly reduced carbon tetrachloride (CCl4)-induced inflammatory infiltration, pro-inflammatory cytokine release, and myeloperioxide (MPO) activity, as well as improved liver function in CCl4-treated mice. Additionally, MGIVE also significantly impaired CCl4-induced increases in liver fibrotic marker expression, such as collagen type I and hypoxia inducible factor-1alpha (HIF-1alpha). Further investigation indicated that the possible molecular target of MGIVE is the toll-like receptor 4 (TLR4)-mediated pathway, and MGIVE treatment significantly prevented CCl4-induced transforming growth factor-beta1 (TGF-beta1) overexpression and the phosphorylation of mitogen activated protein kinase (MAPK) in vivo. In vitro tests of HSCs or RAW 264.7 cells challenged with TGF-beta1 or lipopolysaccharide (LPS) demonstrated that TLR4 expression partly mediated the anti-fibrotic effects of MGIVE. In conclusion, supplementation with MGIVE may attenuate liver fibrosis through inhibiting the TLR4 signaling pathway, including MyD88 and MAPKs, as well as HIF-1alpha. MGIVE may act as a therapeutic potential drug for the treatment of liver fibrosis via the TLR4/HIF-1alpha cohort signaling pathway.
Antiproliferative Activity of Triterpene Glycoside Nutrient from Monk Fruit in Colorectal Cancer and Throat Cancer.[Pubmed:27304964]
Nutrients. 2016 Jun 13;8(6). pii: nu8060360.
Colorectal cancer and throat cancer are the world's most prevalent neoplastic diseases, and a serious threat to human health. Plant triterpene glycosides have demonstrated antitumor activity. In this study, we investigated potential anticancer effects of Mogroside IVe, a triterpenoid glycoside from monk fruit, using in vitro and in vivo models of colorectal and laryngeal cancer. The effects of Mogroside IVe on the proliferation of colorectal cancer HT29 cells and throat cancer Hep-2 cells were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and the expression levels of p53, phosphorylated ERK1/2, and MMP-9 were analyzed by western blotting and immunohistochemistry. The results indicated that Mogroside IVe inhibited, in a dose-dependent manner, the proliferation of HT29 and Hep-2 cells in culture and in xenografted mice, which was accompanied by the upregulation of tumor suppressor p53, and downregulation of matrix metallopeptidase 9 (MMP-9) and phosphorylated extracellular signal-regulated kinases (ERK)1/2. This study revealed the suppressive activity of Mogroside IVe towards colorectal and throat cancers and identified the underlying mechanisms, suggesting that Mogroside IVe may be potentially used as a biologically-active phytochemical supplement for treating colorectal and throat cancers.
[A new natural saponin from fruits of Siraitia grosvenorii].[Pubmed:21710738]
Zhongguo Zhong Yao Za Zhi. 2011 Mar;36(6):721-4.
OBJECTIVE: To study the chemical constituents in the fruits of Siraitia grosvenorii. METHOD: Isolation and purification of the constituents were carried out on column chromatography. Their structures were identified by NMR and MS spectral analysis. RESULT: Six compounds were isolated and elucidated as mogroside IIIA1 (1), siamenoside I (2), mogroside IVa (3), Mogroside IVe (4), mogroside V (5) and 11-oxo-mogroside V(6), respectively. CONCLUSION: Compound 1, mogrol-24-O-beta-D-glucopyranosyl (1 --> 2)-[beta-D-glucopyranosyl(1 --> 6) ]-beta-D-glucopyranoside, was identified as a new natural product from the fruits of S. grosvenorii.
